Vanguard Capital Management
ATRA icon

Vanguard Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Vanguard Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.84M Buy
247,047
+29,185
+13% +$233K ﹤0.01% 3306
2026
Q1 		$1.03M Buy
+217,862
New +$1.33M ﹤0.01% 3545

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management's ATRA Position: Q2 2026 in Review

Vanguard Capital Management increased its Atara Biotherapeutics (ATRA) stake by 13% in Q2 2026, buying an estimated $233K and bringing the position to 247,047 shares worth $2.84M. The position accounts for ﹤0.01% of the portfolio, ranked #3306.

Vanguard Capital Management first reported a position in ATRA in Q1 2026 and has held it in 2 quarters since. 33 funds tracked by Wall St. Rank hold ATRA as of Q2 2026.

  • Vanguard Capital Management held 247,047 shares of Atara Biotherapeutics worth $2.84M as of Q2 2026.
  • Vanguard Capital Management bought 29,185 Atara Biotherapeutics shares in Q2 2026, an estimated $233K.
  • Atara Biotherapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3306 holding.
  • Vanguard Capital Management first reported a position in Atara Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 33 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.